RxDoctor Payments Data

Hailee Mikkelsen, NP

Family · Beloit, WINPI 1689335556

Payments from drug & device makers

$2,187in general payments, 2019–2025

Across 70 payments — averaging $31.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$795
  • Medtronic$524
  • Lilly USA, LLC$266
  • Dexcom, Inc.$230
  • Corcept Therapeutics$97
  • Xeris Pharmaceuticals, Inc.$90
  • plus $186 from 4 others

What the payments were for

  • Travel & lodging$1828%
  • Food & beverage$2,00592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,187 in reported general payments places this provider in the 90th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$17,685
Medicare patients
101
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$197,413
MounjaroTirzepatide104$135,826
JardianceEmpagliflozin125$125,221
TrulicityDulaglutide57$71,449
Tresiba Flextouch U-200Insulin Degludec52$52,221
Fiasp FlextouchInsulin Aspart (Niacinamide)43$40,399
RybelsusSemaglutide29$33,381
Humalog Kwikpen U-100Insulin Lispro106$32,162
Tresiba Flextouch U-100Insulin Degludec42$28,614
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$26,119
Lantus SolostarInsulin Glargine,hum.Rec.Anlog174$21,453
Humalog Kwikpen U-200Insulin Lispro18$21,183
FarxigaDapagliflozin Propanediol17$18,772
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$18,044
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$17,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$795$239,636202 claims
Lilly USA, LLCMounjaro, Trulicity$266$207,276161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,273 family providers in Wisconsin.

Other family in Beloit

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →